Press "Enter" to skip to content

Pfizer And BioNTech Face Lawsuit Over mRNA Technology, Accused Of Infringing Patents Filed About One Decade Before COVID-19

By Danielle

 

GlaxoSmithKline (GSK) has sued Pfizer and BioNTech, accusing the COVID-19 jab manufacturers of infringing patents related to mRNA technology in the experimental shots. 

“GSK Biologicals is the sole owner and assignee of numerous United States patents directed to formulations comprising lipids and messenger ribonucleic acid (‘mRNA’) molecules encoding an immunogen, and methods of administering the same,” the lawsuit read.

“In 2008, more than a decade before the SARS-CoV-2 (2019) coronavirus disease (COVID-19) pandemic, Andrew Geall, an accomplished formulation scientist and the named inventor of the Patents-in-Suit, joined a team of talented researchers working under the leadership of vaccinologist Christian Mandl (the ‘Mandl team’) focused on developing mRNA vaccines. These individuals discovered formulations comprising lipids and mRNA molecules encoding a viral immunogen that provide protection from viral infection. The Mandl team described the inventions now claimed in the Patents-in-Suit, in patent applications filed in 2010,” it continued.

Per Reuters:

A Pfizer spokesperson said in a statement that the company is “confident in our IP position around Comirnaty” and intends to “vigorously defend” against GSK’s claims. A BioNTech spokesperson declined to comment on the complaint.

A GSK spokesperson said the company believes its patents “provided the foundational technology used in Pfizer and BioNTech’s COVID-19 mRNA vaccines,” and that it is “willing to license these patents on commercially reasonable terms and to ensure continued patient access” to the shots…

READ FULL ARTICLE HERE… (100percentfedup.com)

Live Stream + Chat (zutalk.com)

 


Home | Caravan to Midnight (zutalk.com)

We Need Your Help To Keep Caravan To Midnight Going,

Please Consider Donating To Help Keep Independent Media Independent

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Breaking News: